{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tenofovir+Disoproxil+Fumarate&page=6", "query": { "intervention": "Tenofovir Disoproxil Fumarate", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 307, "total_pages": 31, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tenofovir+Disoproxil+Fumarate&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tenofovir+Disoproxil+Fumarate&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T03:34:19.788Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05957913", "title": "Effects of Antiviral Therapies on Epstein-Barr Virus Replication", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Truvada (tenofovir/emtricitabine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2023-06-05", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-10-13T03:34:19.788Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05957913" }, { "nct_id": "NCT01818596", "title": "Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2013-03-27", "completion_date": "2018-07-18", "has_results": true, "last_update_posted_date": "2020-03-02", "last_synced_at": "2026-10-13T03:34:19.788Z", "location_count": 51, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Hayward", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01818596" }, { "nct_id": "NCT00896051", "title": "TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Acquired Immunodeficiency Syndrome" ], "interventions": [ { "name": "Atazanavir (ATV) 300 mg", "type": "DRUG" }, { "name": "Atazanavir (ATV) 400 mg", "type": "DRUG" }, { "name": "Ritonavir (rtv) 100 mg", "type": "DRUG" }, { "name": "Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs)", "type": "DRUG" }, { "name": "Etravirine (ETR) 200 mg", "type": "DRUG" }, { "name": "Tenofovir disoproxil fumarate (TDF) 300 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2009-08", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-10-13T03:34:19.788Z", "location_count": 10, "location_summary": "Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 7 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00896051" }, { "nct_id": "NCT03982186", "title": "A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis B, Chronic" ], "interventions": [ { "name": "JNJ-73763989", "type": "DRUG" }, { "name": "Placebo for JNJ-73763989", "type": "DRUG" }, { "name": "JNJ-56136379", "type": "DRUG" }, { "name": "Placebo for JNJ-56136379", "type": "DRUG" }, { "name": "Nucleos(t)ide Analog (NA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Sciences Ireland UC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 471, "start_date": "2019-08-01", "completion_date": "2022-04-26", "has_results": true, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-10-13T03:34:19.788Z", "location_count": 8, "location_summary": "Bakersfield, California • Los Angeles, California • San Clemente, California + 5 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Clemente", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03982186" }, { "nct_id": "NCT00960622", "title": "Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Truvada", "type": "DRUG" }, { "name": "Combivir", "type": "DRUG" }, { "name": "Trizivir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Luke's-Roosevelt Hospital Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2006-08", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2013-03-04", "last_synced_at": "2026-10-13T03:34:19.788Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00960622" }, { "nct_id": "NCT04616963", "title": "Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hiv", "Hormone Therapy" ], "interventions": [ { "name": "Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg", "type": "DRUG" }, { "name": "Emtricitabine Tenofovir Alafenamide 200/25 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2019-10-24", "completion_date": "2024-01-31", "has_results": false, "last_update_posted_date": "2023-05-06", "last_synced_at": "2026-10-13T03:34:19.788Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04616963" }, { "nct_id": "NCT00660972", "title": "Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Raltegravir", "type": "DRUG" }, { "name": "Emtricitabine/tenofovir disoproxil fumarate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2008-05", "completion_date": "2010-04", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-10-13T03:34:19.788Z", "location_count": 15, "location_summary": "San Diego, California • Aurora, Colorado • Chicago, Illinois + 10 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00660972" }, { "nct_id": "NCT02478632", "title": "Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Subjects do not receive study medication in this study 202094", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2015-06-12", "completion_date": "2018-08-17", "has_results": true, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-10-13T03:34:19.788Z", "location_count": 7, "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02478632" }, { "nct_id": "NCT01400412", "title": "Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Darunavir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Tenofovir disoproxil fumarate", "type": "DRUG" }, { "name": "Emtricitabine", "type": "DRUG" }, { "name": "Placebo for Tenofovir disoproxil fumarate", "type": "DRUG" }, { "name": "Placebo for Maraviroc", "type": "DRUG" }, { "name": "Maraviroc", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 262, "start_date": "2012-01-17", "completion_date": "2014-06-30", "has_results": true, "last_update_posted_date": "2024-10-15", "last_synced_at": "2026-10-13T03:34:19.788Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01400412" }, { "nct_id": "NCT01772823", "title": "An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "3MV", "type": "BEHAVIORAL" }, { "name": "PCC", "type": "BEHAVIORAL" }, { "name": "Emtricitabine/tenofovir (FTC/TDF (Truvada®))", "type": "DRUG" } ], "intervention_types": [ "BEHAVIORAL", "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "22 Years", "sex": "MALE", "summary": "18 Years to 22 Years · Male only" }, "enrollment_count": 200, "start_date": "2012-11", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2018-01-17", "last_synced_at": "2026-10-13T03:34:19.788Z", "location_count": 12, "location_summary": "Los Angeles, California • Aurora, Colorado • Miami, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01772823" } ] }